Literature DB >> 18611565

Biological response modifiers and infectious diseases: actual and potential therapeutic agents.

J J Rusthoven1.   

Abstract

Biological response modifiers (BRMs) are agents which can modify the immune response to cancer or invasion of the organism by infectious agents. An explosive appearance of new BRMs has resulted from the development of recombinant gene technology and the availability of monoclonal antibodies. Colony-stimulating factors first became available for the prevention of neutropenia but may also have a role in the treatment of infections. Interleukin-1 is being tested as a modular of hematopoiesis and may be useful as a helper factor for T- and B-cell function. Immunoglobulins are being used against viral and bacterial infections while interferons can prevent viral upper respiratory infections and suppress or irradicate some viral hepatitides. Other BRMs which show promise include chemical agents and traditional herbal medicines.

Entities:  

Year:  1994        PMID: 18611565      PMCID: PMC7135342          DOI: 10.1016/0924-8579(94)90050-7

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  194 in total

Review 1.  Regulatory functions of the vascular endothelium.

Authors:  J R Vane; E E Anggård; R M Botting
Journal:  N Engl J Med       Date:  1990-07-05       Impact factor: 91.245

2.  Comparative studies of impurities in intravenous immunoglobulin preparations.

Authors:  J L Lundblad; G Mitra; M M Sternberg; D D Schroeder
Journal:  Rev Infect Dis       Date:  1986 Jul-Aug

3.  Effects of interleukin-1 on hematopoietic progenitors: evidence of stimulatory and inhibitory activities in a primate model.

Authors:  C Gasparetto; J Laver; M Abboud; A Gillio; C Smith; R J O'Reilly; M A Moore
Journal:  Blood       Date:  1989-08-01       Impact factor: 22.113

4.  Administration of human leukocyte interferon in herpes zoster. I. Safety, circulating, antiviral activity, and host responses to infection.

Authors:  G W Jordan; R P Fried; T C Merigan
Journal:  J Infect Dis       Date:  1974-07       Impact factor: 5.226

5.  Zoster immune globulin prophylaxis of disseminated zoster in compromised hosts. A randomized trial.

Authors:  D A Stevens; T C Merigan
Journal:  Arch Intern Med       Date:  1980-01

6.  Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study.

Authors:  E M Hersh; G Brewton; D Abrams; J Bartlett; J Galpin; P Gill; R Gorter; M Gottlieb; J J Jonikas; S Landesman
Journal:  JAMA       Date:  1991-03-27       Impact factor: 56.272

7.  Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer.

Authors:  J Nemunaitis; S N Rabinowe; J W Singer; P J Bierman; J M Vose; A S Freedman; N Onetto; S Gillis; D Oette; M Gold
Journal:  N Engl J Med       Date:  1991-06-20       Impact factor: 91.245

8.  Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen.

Authors:  D H Smith; R A Byrn; S A Marsters; T Gregory; J E Groopman; D J Capon
Journal:  Science       Date:  1987-12-18       Impact factor: 47.728

9.  Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children.

Authors:  V G Hemming; W Rodriguez; H W Kim; C D Brandt; R H Parrott; B Burch; G A Prince; P A Baron; R J Fink; G Reaman
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

10.  Biological properties of a CD4 immunoadhesin.

Authors:  R A Byrn; J Mordenti; C Lucas; D Smith; S A Marsters; J S Johnson; P Cossum; S M Chamow; F M Wurm; T Gregory; J E Groopman; D J Capon
Journal:  Nature       Date:  1990-04-12       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.